Results 251 to 260 of about 73,275 (286)

Bispecific Antibodies Versus Chimeric Antigen Receptor T‐Cell Therapy in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou, Husna Irfan Thalib, Fayza Akil, Samia Zuhair Sabbagh, Hala Sofian Abou, Mable Pereira, Fatma ElSayed Hassan   +6 more
wiley   +1 more source

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. [PDF]

Int J Mol Sci
Givi S, Lohnes BJ, Ebrahimi S, Riedel S, Khokhali S, Khan SA, Keller M, Wölfel C, Echchannaoui H, Bockamp E, Andre MC, Abken H, Theobald M, Hartwig UF.   +13 more
europepmc   +1 more source

GPR183‐mediated activation of PI3K is a potential biomarker for immunotherapy in lung cancer

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Anti‐PD1 treatment and PI3Kγ inhibition had remarkable therapeutic performance on CD4+ Tcm and CD4+ Tn in lung cancer through potential regulation of PI3K pathway with participation of GPR183. Abstract Background As one of commonly used immune checkpoint inhibition therapies, PD1 monoclonal antibodies exhibit a promising cancer immunotherapy approach ...
Ling Ye, Nannan Zheng, Fangming Liu, Huirong Fu, Yifei Liu, Ying Yang, Ruixue Qi, Duojiao Wu, Lin Shi, Dongli Song   +9 more
wiley   +1 more source

Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy. [PDF]

Nat Commun
Zheng T, Ramanathan K, Ormhøj M, Hansen MR, Halldórsdóttir HR, Li H, Munk KK, Rodriguez-Pardo C, Friis RUW, Seder I, Heegaard PMH, Qvortrup K, Abken H, Sun Y, Hadrup SR.   +14 more
europepmc   +1 more source

The Current Landscape of Modular CAR T Cells. [PDF]

Int J Mol Sci
Joechner AH, Mach M, Li Z.
europepmc   +1 more source

Second signals for cancer immunotherapy. [PDF]

J Immunother Cancer
Olejniczak SH, Lotze MT, Skokos D.
europepmc   +1 more source

The broad spectrum of cancer and immunotherapy: achievements and limitations. [PDF]

Front Immunol
Aman A, Toledo B, González-Titos A, Picon-Ruiz M, Hernández-Camarero P.   +4 more
europepmc   +1 more source

Opportunities and challenges harnessing antigen-specific CD4+ regulatory T cells in inflammatory bowel disease. [PDF]

Front Immunol
Kümmel J, Schlegel N, Wagner JC.
europepmc   +1 more source

CAR Therapies: Ex Vivo and In Vivo Potential of Exosomes and Biomimetic Nanoparticles. [PDF]

Cancers (Basel)
Tkachenko E, Ponomareva N, Evmenov K, Kachanov A, Brezgin S, Kostyusheva A, Chulanov V, Volchkova E, Lukashev A, Kostyushev D, Timashev P.   +10 more
europepmc   +1 more source